AR-C239

structure given in first source; alpha(2B)-selective adrenoreceptor

Also Known As:

2-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-4,4-dimethyl-(2H,4H)-isoquinoline-1,3-dione; 2-(2-(4-(o-methoxyphenyl)piperazine-1-yl)ethyl)-4,4-dimethyl-1,3(2H,4H)isoquinolinedione; AR C239; AR-C 239; ARC 239; ARC-239; 1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - AR-C239: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - AR-C239: 10

Experts

1.	Bartolini, Alessandro: 1 article (08/2004)
2.	Galeotti, Nicoletta: 1 article (08/2004)
3.	Ghelardini, Carla: 1 article (08/2004)

Related Diseases

1.	Bradycardia 09/01/1988 - "The alpha 1-adrenoceptor blocking agent, AR-C 239, decreased the bradycardia induced by high doses of RU 24969. " 11/19/1982 - "AR-C 239 (300 micrograms/kg i.v.) did not change the heart rate in control (without pretreatment) and bilaterally vagotomized normotensive rats, but induced significant bradycardia in rats pretreated with a beta-adrenoceptor blocking drug. " 11/01/1983 - "In anaesthetized and bilaterally vagotomized dogs, reflex bradycardia elicited by intravenous injection of noradrenaline was facilitated by AR-C 239, a new alpha 1-adrenoceptor blocking drug and inhibited by the alpha 2-adrenoceptor antagonist, yohimbine. "
2.	Hypertension (High Blood Pressure) 05/01/1990 - "Effect of hypertension and age on alpha 1-adrenoceptors in rat brain: modulation of [3H] prazosin binding by chronic treatment with desipramine and AR-C239." 07/01/1983 - "In anaesthetized dog, the adrenaline induced hypertension is reversed by both alpha 1- and alpha 2-adrenoceptor blocking agents such as AR-C 239 and yohimbine. "
3.	Heart Failure 04/01/1989 - "AR-C 239 was tested in 11 patients (49 +/- 11 years old) with left heart failure, who had not received any previous treatment. " 01/01/1987 - "These results show that AR-C 239 is a powerful vasodilator without secondary beta mimetic effects or influence on LV contractility; it may provide an effective means of treating cardiac failure."
4.	AIDS-Related Complex (ARC) 01/01/1980 - "AR-C239 did not modify the functioning of the baroreflex arc. " 11/01/1991 - "2. Binding constants for 14 compounds for the three rat kidney alpha 2-adrenoceptor subtypes were determined by the simultaneous computer modelling of plain and ARC 239- and guanoxabenz-masked drug competition curves, plain ARC 239 and guanoxabenz competition curves as well as ARC 239-masked guanoxabenz competition curves. " 11/01/1991 - "1. Simultaneous computer modelling of plain and ARC 239- and guanoxabenz-masked [3H]-RX821002 saturation curves, plain ARC 239 and guanoxabenz competition curves as well as ARC 239-masked guanoxabenz competition curves revealed that the drugs bound to three alpha 2-adrenoceptor subtypes in the rat kidney with grossly differing selectivities. "
5.	Tachycardia (Tachyarrhythmias) 01/01/1980 - "AR-C239 did not change the tachycardia induced by stimulation of the cardiac nerve in dogs and, at least in this preparation, seems to be a specific alpha 1-adrenoceptor blocking drug. "

Related Drugs and Biologics

1.	Prazosin (Minipress)
2.	Yohimbine (Yocon)
3.	Vasodilator Agents (Vasodilators)
4.	Adrenergic Receptors (Adrenergic Receptor)
5.	Phenylephrine (Neo-Synephrine)
6.	Norepinephrine (Noradrenaline)
7.	Guanabenz (BR 750)
8.	Epinephrine (Adrenaline)
9.	Desipramine (Pertofrane)
10.	Clonidine (ST 155)

Related Therapies and Procedures

1.	Intravenous Injections